Literature DB >> 16040919

Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter.

Kinuko Kono1, Yoshiyuki Okano, Keiko Nakayama, Yutaka Hase, Sosuke Minamikawa, Nozomi Ozawa, Hiroyuki Yokote, Yuichi Inoue.   

Abstract

PURPOSE: To prospectively determine the relationship between serum phenylalanine levels and apparent diffusion coefficient (ADC) values in the cerebral white matter of patients with phenylketonuria (PKU).
MATERIALS AND METHODS: Institutional review board approval was obtained, and participants provided informed consent. Magnetic resonance (MR) imaging, which included T1- and T2-weighted, fluid-attenuated inversion-recovery (FLAIR), and diffusion-weighted examinations, was performed in 21 patients with PKU (nine male and 12 female patients; age range, 3-44 years; mean age, 19.4 years). ADC values in deep cerebral white matter were calculated for each patient. Serum phenylalanine levels were obtained in all patients within 12 days after MR imaging. Serum phenylalanine levels were measured in 16 patients 1 year before MR imaging. ADC values in cerebral white matter and serum phenylalanine levels were compared. A total of 21 control subjects (12 male and nine female patients; age range, 3-33 years; mean age, 20.6 years) underwent MR imaging. ADC values in cerebral white matter were compared with serum phenylalanine levels by using the Pearson correlation.
RESULTS: Abnormal high signal intensity in white matter on T2-weighted and FLAIR MR images was noted in patients with PKU who had serum phenylalanine levels of more than 8.5 mg/dL (514.2 micromol/L). Diffusion in posterior deep cerebral white matter tended to be restricted in patients when increased serum phenylalanine levels were measured after MR imaging (r = -0.62). There was a correlation between ADC values in posterior cerebral white matter and serum phenylalanine levels measured 1 year before MR imaging (r = -0.77). ADCs of control subjects were significantly higher than ADCs of patients with PKU (P < .005).
CONCLUSION: Posterior deep white matter in patients with PKU and a serum phenylalanine level of more than 8.5 mg/dL showed high signal intensity in white matter on T2-weighted and FLAIR MR images and revealed decreased ADC. We suggest that to avoid brain-restricted diffusion due to hyperphenylalanemia, patients with PKU should maintain serum phenylalanine levels of less than 8.5 mg/dL (514.2 micromol/L).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16040919     DOI: 10.1148/radiol.2362040611

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  21 in total

Review 1.  Magnetic resonance imaging of myelin.

Authors:  Cornelia Laule; Irene M Vavasour; Shannon H Kolind; David K B Li; Tony L Traboulsee; G R Wayne Moore; Alex L MacKay
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

Review 2.  New frontiers in neuroimaging applications to inborn errors of metabolism.

Authors:  Morgan J Prust; Andrea L Gropman; Natalie Hauser
Journal:  Mol Genet Metab       Date:  2011-06-30       Impact factor: 4.797

3.  Age-related decline in the microstructural integrity of white matter in children with early- and continuously-treated PKU: a DTI study of the corpus callosum.

Authors:  Desiree A White; Lisa Tabor Connor; Binyam Nardos; Joshua S Shimony; Rebecca Archer; Abraham Z Snyder; Asif Moinuddin; Dorothy K Grange; Robert D Steiner; Robert C McKinstry
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

4.  Tract-based evaluation of white matter damage in individuals with early-treated phenylketonuria.

Authors:  Huiling Peng; Dawn Peck; Desirée A White; Shawn E Christ
Journal:  J Inherit Metab Dis       Date:  2013-09-17       Impact factor: 4.982

5.  Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.

Authors:  Anna Hood; Jo Ann V Antenor-Dorsey; Jerrel Rutlin; Tamara Hershey; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desiree A White
Journal:  Mol Genet Metab       Date:  2014-11-13       Impact factor: 4.797

6.  White matter integrity and executive abilities in individuals with phenylketonuria.

Authors:  Jo Ann V Antenor-Dorsey; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

7.  Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria.

Authors:  Renzo Manara; Alessandro P Burlina; Valentina Citton; Mario Ermani; Francesco Vespignani; Carla Carollo; Alberto B Burlina
Journal:  Neuroradiology       Date:  2009-08-04       Impact factor: 2.804

8.  White matter integrity and executive abilities following treatment with tetrahydrobiopterin (BH4) in individuals with phenylketonuria.

Authors:  Desirée A White; Jo Ann V Antenor-Dorsey; Dorothy K Grange; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Shawn E Christ
Journal:  Mol Genet Metab       Date:  2013-07-19       Impact factor: 4.797

Review 9.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

10.  The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study.

Authors:  V Leuzzi; M Tosetti; D Montanaro; C Carducci; C Artiola; C Carducci; I Antonozzi; M Burroni; F Carnevale; F Chiarotti; T Popolizio; G M Giannatempo; V D'Alesio; T Scarabino
Journal:  J Inherit Metab Dis       Date:  2007-01-23       Impact factor: 4.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.